Hematology TimesCHMP supports new indication for venetoclaxSeptember 23, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesStress linked to disease markers in CLLSeptember 20, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesNICE rejects DLBCL indication for CAR T-cell therapySeptember 20, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
Hematology TimesGuidelines for proton therapy in mediastinal lymphomasSeptember 19, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesRisks of watchful waiting in follicular lymphomaSeptember 19, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsBest practices defined for proton therapy in mediastinal lymphomasSeptember 18, 2018Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsVenetoclax label now includes MRD dataSeptember 12, 2018CLLAggressive LymphomasLeukemia, Myelodysplasia, TransplantationB Cell Lymphoma
Hematology TimesMRD data added to venetoclax labelSeptember 12, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasB Cell Lymphoma
Hematology NewsTP53 mutation plus complex karyotype equals poor prognosisSeptember 10, 2018Mantle Cell LymphomaLymphoma & Plasma Cell DisordersAggressive LymphomasB Cell Lymphoma
Hematology NewsNovartis nabs first CAR T approval in CanadaSeptember 7, 2018ALLAggressive LymphomasImmunotherapyFollicular LymphomaB Cell Lymphoma
Hematology TimesFirst CAR T-cell therapy approved in CanadaSeptember 7, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsPharmacyALLAggressive LymphomasFollicular Lymphoma
Hematology TimesRegimens produce similar results in FLSeptember 7, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesIbrutinib maintains efficacy over timeSeptember 7, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsRESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patientsSeptember 6, 2018CLLAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsEngland green-lights coverage of one CAR T-cell therapySeptember 6, 2018Business of MedicinePractice ManagementImmunotherapyALLCellular TherapyAggressive LymphomasB Cell Lymphoma
